Shanghai Saijin Biopharmaceutical - About the company
Shanghai Saijin Biopharmaceutical is a series A company based in Pudong (China), founded in 2000. It operates as a Biopharma company developing recombinant proteins and MAbs. Shanghai Saijin Biopharmaceutical has raised an undisclosed amount in funding. The company has 367 active competitors, including 41 funded and 52 that have exited. Its top competitors include companies like Novartis, Catalent and Surrozen.
Company Details
Celgen Biopharma, formed as a JV between Shanghai Pharmaceutical (Group) and the United States Kangda Biotechnology Holdings, is engaged in the research, development, and manufacturing of recombinant proteins and monoclonal antibodies. Their first product was an injectable recombinant human type II tumor necrosis factor receptor-antibody fusion protein and is approved by SFDA for ankylosing spondylitis and is being evaluated for rheumatoid arthritis and psoriasis.
- Website
- celgenpharm.com
- Email ID
- *****@celgenpharm.com
- Phone Number
- +86 **********
Key Metrics
Founded Year
2000
Location
Pudong, China
Stage
Series A
Latest Funding Round
Investors
Ranked
82nd among 367 active competitors
Employee Count
51 - 200 as on Jul 01, 2024
Sign up to download Shanghai Saijin Biopharmaceutical's company profile
Shanghai Saijin Biopharmaceutical's funding and investors
Shanghai Saijin Biopharmaceutical has raised funding over 1 round. Its latest funding round was a Series A round on Jul 2009 for $*****. 2 investors participated in its latest round. Shanghai Saijin Biopharmaceutical has 4 institutional investors.
Here is the list of recent funding rounds of Shanghai Saijin Biopharmaceutical:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jul 2009 | 9420919 | Series A | 1950826 | 8636577 | 6860985 | 9802337 |
Access funding benchmarks and valuations. Sign up today!View details of Shanghai Saijin Biopharmaceutical's funding rounds and investors
Shanghai Saijin Biopharmaceutical's founders and board of directors
Founder? Claim ProfileShanghai Saijin Biopharmaceutical's employee count trend
Shanghai Saijin Biopharmaceutical has 51 - 200 employees as of Jul 24. Here is Shanghai Saijin Biopharmaceutical's employee count trend over the years:
Uncover Shanghai Saijin Biopharmaceutical's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Shanghai Saijin Biopharmaceutical's Competitors and alternates
Top competitors of Shanghai Saijin Biopharmaceutical include Novartis, Catalent and Surrozen. Here is the list of Top 10 competitors of Shanghai Saijin Biopharmaceutical, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Novartis 1996, Basel (Switzerland), Public | R&D focused on manufacturing of drugs for multiple therapeutic areas | - | 70/100 | |
2nd | Catalent 2007, Somerset (United States), Acquired | Provider of development, manufacturing, and packaging solutions for medicines and supplements | - | 68/100 | |
3rd | Surrozen 2016, San Francisco (United States), Public | Pioneering targeted regenerative antibodies to repair tissue and restore organ function | $133M | 65/100 | |
4th | Organic synthesis, analytical, and peptide chemistry services for drug discovery and development | - | 62/100 | ||
5th | BioFactura 2004, Frederick (United States), Series B | Biosimilars, biodefense, and biomanufacturing company dedicated to innovation and global biomedical needs | $7.8M | 56/100 | |
6th |  Full-Life Technologies 2021, Shanghai (China), Series C | Provider of discovery, development, production, and logistics services for of nuclear medicines | $200M | 55/100 | |
7th | Tirupati Medicare 1980, Paonta Sahib (India), Series B | Contract manufacturer of pharmaceutical products | $51.5M | 55/100 | |
8th |  Acclinate 2020, Birmingham (United States), Series A | Provider of clinical trial services to biopharma sector | $12M | 54/100 | |
9th |  AmplifyBio 2021, Hilliard (United States), Deadpooled | Provider of contract research, development, and manufacturing services for biologic drugs | $230M | 54/100 | |
10th |  Curia 1991, Albany (United States), Acquired | Provider of drug research & development, testing, and consulting services | - | 52/100 | |
82nd |  Shanghai Saijin Biopharmaceutical 2000, Pudong (China), Series A | Biopharma company developing recombinant proteins and MAbs | - | 28/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Shanghai Saijin Biopharmaceutical's competitors? Click here to see the top ones
Shanghai Saijin Biopharmaceutical's Investments and acquisitions
Shanghai Saijin Biopharmaceutical has made no investments or acquisitions yet.
Are you a Founder ?
FAQs about Shanghai Saijin Biopharmaceutical
Explore our recently published companies
- EraGrow - Calgary based, 2024 founded, Unfunded company
- Datost - San Francisco based, Unfunded company
- Resquad AI - Saudi Arabia based, 2024 founded, Seed company
- Twentyfour Industries - Munchen based, 2024 founded, Series B company
- Ask - Miami based, 2008 founded, Unfunded company
- La Monnaie - Brussels based, 1700 founded, Funding Raised company
